drugset / Trial / NCT00649805

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00649805

Phase 1 Completed 24 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following by a single, oral 300 mg (1 x 300 mg) dose administration sprinkled on one tablespoon of applesauce under fasting conditions.

Timeline

Start
2006-01
Primary completion
2006-01
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Verapamil Other / unclassified 300 mg Oral

Indications

No indication recorded.